Project Grant R43AI138864

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,514,746 to Weill Medical College of Cornell University to develop comprehensive microbial biomarkers for diagnosing and predicting infections in kidney transplant recipients. The key objectives are to: 1) Develop a fecal short-chain fatty acid (SCFA) assay to predict infection risk, and 2) Develop blood and urine...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Datirium LLC, a for-profit limited liability company in Cincinnati, Ohio. The project aims to develop an automated computational pipeline to process single-cell RNA and T cell receptor sequencing data from kidney biopsies and potentially urine samples. The goal is to identify alloreactive expanded cytotoxic T cell clones...

This $1,361,442 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop an economical and rapid molecular diagnostic system for detecting Hepatitis C Virus (HCV) and HIV from whole blood samples. The key products and services to be delivered include: Adapting and automating RNA sample extraction and stabilization (RNAES) technology to enable HCV/HIV RNA extraction from...

This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $196,344 to Emory University to identify immunologic biomarkers that can predict clinical outcomes in solid organ transplant patients with bloodstream infections. The key objectives are to: 1) Identify cytokine, chemokine, and biomarkers associated with septic shock and 30-day mortality in this patient population; 2)...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,989 to Day Zero Diagnostics Inc. to develop EPIXACT-FMT, a metagenomic, pharmacovigilance assay for microbiota therapeutics safety. The goal of this project is to innovate sample preparation, deep sequencing, and bioinformatic analysis to achieve strain-level resolution of metagenomic donor samples used for...

This $841,520 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to study microbial biomarkers of antimicrobial resistance (AMR) colonization in solid organ transplant recipients (SOTR). The primary objectives are to: 1) Leverage an existing cohort and biobank of over 2,200 samples from liver transplant patients to perform whole-genome sequencing of clinical isolates and...

The National Cancer Institute (NCI) awarded a $601,364 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Data Driven Bioscience Inc. to develop and validate a comprehensive genomic approach called "DuoSeq" for diagnosing blood cancers. DuoSeq utilizes both DNA and RNA sequencing from a single workflow to provide a range of diagnostic readouts, including detecting mutations, copy number alterations, translocations, and gene expression markers. This...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs). The $300,000 award to Baebies, Inc., a manufacturer of advanced medical diagnostic equipment based in Durham, North Carolina, will support the creation of a panel of novel STI viability PCR (V-PCR) assays. These...

This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $1,281,272 to the Translational Genomics Research Institute (TGen) to conduct a comprehensive, longitudinal, virome-wide serological analysis of viral infections in Type 1 Diabetes (T1D) birth cohorts. The goal is to identify viral associations with autoimmunity and the onset of T1D...